Shares of WW International Inc (NASDAQ:WW) rose 3.7% in premarket trading Tuesday following the company announcement that its WeightWatchers Med+ offering will support Medicare beneficiaries seeking access to GLP-1 weight-loss medications via the Medicare GLP-1 Bridge Program.
Under the bridge program, eligible Medicare beneficiaries will be able to obtain specified GLP-1 products for $50 per month. The list of covered therapies includes Zepbound, KwikPen, Foundayo, and both pen and pill forms of Wegovy. The program has a defined duration, running from July 1, 2026 through December 31, 2027.
WeightWatchers Med+ will provide clinical management for patients when medication is appropriate, including prescribing where indicated and managing care related to these treatments. The service will also assist members in navigating insurance processes, completing paperwork, and securing prior authorizations.
Eligibility for the Medicare Bridge program is limited by three conditions: beneficiaries must be covered under Medicare Part D, must meet the clinical eligibility criteria, and must have an active prescription for an eligible GLP-1 medication. The program requires that the medication be taken in conjunction with ongoing lifestyle interventions, specifically nutrition and physical activity.
WW provided outcome data for its Med+ population that links behavioral engagement to improved results. Among Med+ members who were prescribed a GLP-1 medication, those who regularly participated in the GLP-1 Success Program lost on average 29.1% more body weight at 12 months than members who did not engage in behavioral support. In addition, 73% of Med+ participants who received the GLP-1 Success Program reported that WeightWatchers Med+ helped reduce side effects associated with weight-loss medications.
The Med+ model combines clinical oversight with behavioral supports. Services listed by the company include nutrition counseling, tools for medication tracking, refill reminders, and access to specialized GLP-1 coaches. The program also incorporates tailored strength-building guidance aimed at preserving muscle mass and lowering the risk of frailty and falls among older adults.
Implications - The initiative directly touches several market sectors, including healthcare services, pharmaceutical distribution, and senior care. By pairing medication access with behavioral support, WW aims to integrate medical management with lifestyle interventions for Medicare beneficiaries participating in the bridge program.